MRKMerck Sharp & Dohme LLCFinished
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
Solid Tumor · Cutaneous Squamous Cell Carcinoma · Endometrial Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 163 (final count)
- Started
- Sep 29, 2023
- Main results expected
- Mar 12, 2026
- Fully finished
- Mar 12, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Clinical Benefit Rate - Cohort A
Measured over: Up to approximately 22 months
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Investigator - Cohort B
Measured over: Up to approximately 21 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06036836 · record last updated 2026-03-19 · checked 2026-11-09 15:47 UTC